TARA is expected to report earnings to fall -1.11% to -91 cents per share on May 02

A.I.dvisor
at Tickeron.com
05/01/24
Loading...
TARA - Protara Therapeutics
Protara Therapeutics Earnings Graph
Q1'24
Est.
$-0.91
Q4'23
Beat
by $0.02
Q3'23
Beat
by $0.11
Q2'23
Missed
by $0.12
Q1'23
Beat
by $0.08
The last earnings report on December 31 showed earnings per share of -90 cents, beating the estimate of -92 cents. P/B Ratio (0.499) is normal, around the industry mean (10.139). P/E Ratio (0.000) is within average values for comparable stocks, (115.202). TARA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.468). TARA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (0.000) is also within normal values, averaging (226.762). With 281.55K shares outstanding, the current market capitalization sits at 34.07M.
View a ticker or compare two or three
TARADaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage company, which engages in developing treatments for rare and specialty diseases with significant unmet needs.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
345 Park Avenue South
Phone
+1 646 844-0337
Employees
27
Web
http://www.protaratx.com